OVARIAN CANCER and US

open access Feb 13, 2018: The Yet Unrealized Promise of Ovarian Cancer Screening

2018-02-13T21:43:00.002-05:00

The Yet Unrealized Promise of Ovarian Cancer Screening

References

US Preventive Services Task Force. Screening for ovarian cancer: US Preventive Services Task Force recommendation statement [published February 13, 2018]. JAMA. doi:10.1001/jama.2017.21926 Google Scholar

Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: updated evidence report and systematic review for the US Preventive Services Task Force [published February 13, 2018]. JAMA. doi:10.1001/jama.2017.21421 Google Scholar

Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet. 2016;387(10022):945-956.PubMed Google Scholar Crossref

Buys SS, Partridge E, Black A, et al; PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295-2303.PubMed Google Scholar Crossref

Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999;353(9160):1207-1210.PubMed Google Scholar Crossref

Barrett J, Jenkins V, Farewell V, et al; UKCTOCS trialists. Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS). BJOG. 2014;121(9):1071-1079.PubMed Google Scholar Crossref

American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice; Society of Gynecologic Oncology. ACOG Committee opinion No. 716, September 2017. https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/The-Role-of-the-Obstetrician-Gynecologist-in-the-Early-Detection-of-Epithelial-Ovarian-Cancer-in. Accessed January 22, 2018.

Marchetti C, De Felice F, Palaia I, et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all-cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health. 2014;14:150.PubMed Google Scholar Crossref

Rosenthal AN, Fraser LSM, Philpott S, et al; United Kingdom Familial Ovarian Cancer Screening Study collaborators. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the UK Familial Ovarian Cancer Screening Study. J Clin Oncol. 2017;35(13):1411-1420.PubMed Google Scholar Crossref

10.

Skates SJ, Greene MH, Buys SS, et al. Early detection of ovarian cancer using the Risk of Ovarian Cancer Algorithm with frequent CA125 testing in women at increased familial risk. Clin Cancer Res. 2017;23(14):3628-3637.PubMed Google Scholar Crossref

11.

Karlan BY, Thorpe J, Watabayashi K, et al. Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1383-1393.PubMed Google Scholar Crossref

12.

Menon U, McGuire AJ, Raikou M, et al. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Br J Cancer. 2017;117(5):619-627.PubMed Google Scholar Crossref

13.

Sieh W, Salvador S, McGuire V, et al; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium. Tubal ligation and risk of ovarian cancer subtypes. Int J Epidemiol. 2013;42(2):579-589.PubMed Google Scholar Crossref

14.

Garcia C, Martin M, Tucker LY, et al. Experience with opportunistic salpingectomy in a large, community-based health system in the United States. Obstet Gynecol. 2016;128(2):277-283.PubMed Google Scholar Crossref

15.

Powell CB, Swisher EM, Cass I, et al. Long-term follow-up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol. 2013;129(2):364-371.PubMed Google Scholar Crossref

16.

Labidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;8(1):1093.PubMed Google Scholar Crossref

Cancer Network(2) Lynch Syndrome Associated Ovarian Cancer/Endometrioid/Serous Carcinoma

2017-01-27T11:03:00.001-05:00

Cancer Network

OVARIAN CANCER

Lynch Syndrome-Associated Ovarian Cancer Presents Early, Has Good Prognosis

An analysis of Lynch syndrome-associated ovarian cancer found that the malignancy tends to present at an early stage and has a generally good prognosis. Read More »

Endometrioid Ovarian Cancer Presents Earlier, Offers Better Survival Than Serous Carcinoma

Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well. Read More »

Feb 6th Webinar: Looking Ahead: Ovarian Cancer Advocacy in 2017

2017-01-27T11:01:00.001-05:00

Looking Ahead: Ovarian Cancer Advocacy in 2017

Webinar

Ovarian Cancer Advocacy Update: What You Need to Know

Monday, February 6 at 6pm Eastern (Webinar is Free)

With a new Congress and a new President, where do we stand with issues that impact the ovarian cancer community?

Join OCRFA's Vice President of Policy, Chad Ramsey, for an important policy update webinar with a Q&A afterwards.

Chad will be updating us about potential changes to healthcare policy, the status of biomedical research, and OCRFA's proactive policy agenda for 2017.

You won't want to miss this. Can't make the live presentation? Sign up - all registrants will receive a link to the recorded presentation when it's available.

Newly released 2017 Canadian Nonprofit Sector Salary & Benefits Report reveals current compensation trends

2017-01-27T09:28:00.001-05:00

Newly released 2017 Canadian Nonprofit Sector Salary & Benefits Report reveals current compensation trends

Cash compensation continues to grow slowly for many
Average cash compensation increased in the nonprofit sector, except for front-line and support staff, between 2013 and 2016. When increases were received, the majority were less than 3%. The most significant increase was among management/supervisory staff at a cumulative 15% since 2013. This growth will need to be monitored to determine if it is a trend or a temporary spike.

OA: Mesh, graft, or standard repair for women having primary transvaginal anterior or posterior compartment prolapse surgery...

2017-01-27T09:13:00.001-05:00

Mesh, graft, or standard repair for women having primary transvaginal anterior or posterior compartment prolapse surgery: two parallel-group, multicentre, randomised, controlled trials (PROSPECT) - The Lancet

Interpretation

Augmentation of a vaginal repair with mesh or graft material did not improve women's outcomes in terms of effectiveness, quality of life, adverse effects, or any other outcome in the short term, but more than one in ten women had a mesh complication. Therefore, follow-up is vital to identify any longer-term potential benefits and serious adverse effects of mesh or graft reinforcement in vaginal prolapse surgery.

Familial Cancer journal January Index (not an OA publication)

2017-01-27T08:37:00.001-05:00

Familial Cancer

(Seromucinous) Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary

2017-01-27T08:26:00.001-05:00

abstract
Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary

The 2014 World Health Organization Classification of Tumors of Female Reproductive Organs endorsed the new category of seromucinous carcinoma, a neoplasm that exhibits morphologic and immunophenotypic overlap with other histotypes of ovarian carcinoma. The goal of this study was to determine whether seromucinous carcinoma was a distinct histotype by assessing its diagnostic reproducibility and comparing its molecular composition to the 5 major histotypes of ovarian carcinoma. Thirty-two tumors diagnosed as seromucinous carcinomas from 2 centers were studied. Eighteen cases were randomly selected for a review set comprising a total of 50 ovarian carcinomas of various histotypes. Morphologic histotype was independently assessed by 4 pathologists. For the 32 seromucinous carcinomas, a histotype-specific immunophenotype was assigned using a diagnostic immunohistochemical panel. Histotype-specific genotype was assigned using a combination of immunohistochemistry and targeted next-generation sequencing for somatic mutations, including genes recurrently mutated in ovarian carcinomas. There was low to modest agreement between pathologists with the reference diagnosis of seromucinous carcinoma, ranging from 39% to 56% for the 4 observers. The immunophenotype was not unique but overlapped predominantly with endometrioid and to a lesser extent with mucinous and low-grade serous carcinoma. Genomic and immunohistochemical alterations were detected in a number of target genes, including KRAS (70%), PIK3CA (37%), PTEN (19%), and ARID1A (16%); no CTNNB1 mutations were identified. Nine cases (30%) harbored concurrent KRAS/PIK3CA mutations. An endometrioid genotype was assigned to 19 cases, a low-grade serous genotype to 9, and a mucinous genotype to 1 and 3 cases were uninformative. Integrating morphology, immunophenotype, and genotyping resulted in reclassifying the seromucinous carcinomas to endometrioid 23/32 (72%), low-grade serous 8/32 (25%), and mucinous 1/32 (3%). The morphologic diagnosis of seromucinous carcinomas is not very reliable and it does not exhibit a distinct immunophenotype or genotype. The molecular features overlap mostly with endometrioid and low-grade serous carcinomas. Our data suggest the category of seromucinous carcinoma be discontinued as ancillary molecular tests can assign cases to one of the major histotypes.

Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment

2017-01-26T20:49:00.001-05:00

abstract AACR Cancer Research

With the recent advent of immunotherapy, there is a critical need to understand immune cell interactions in the tumor microenvironment in both pan-cancer and tissue-specific contexts. Multi-dimensional datasets have enabled systematic approaches to dissect these interactions in large numbers of patients, furthering our understanding of the patient immune response to solid tumors. Using an integrated approach, we infered the infiltration levels of distinct immune cell subsets in 23 tumor types from The Cancer Genome Atlas. From these quantities, we constructed a co-infiltration network, revealing interactions between cytolytic cells and myeloid cells in the tumor microenvironment. By integrating patient mutation data, we show that while mutation burden was associated with immune infiltration differences between distinct tumor types, additional factors may explain immunogenic differences between tumors originating from the same tissue. Finally, we examined the prognostic value of individual immune cell subsets as well as how co-infiltration of functionally discordant cell types associated with patient survival. We showed in multiple tumor types that the protective effect of CD8+ T cell infiltration was heavily modulated by co-infiltration of macrophages and other myeloid cell types, suggesting the involvement of myeloid-derived suppressor cells in tumor development. Our findings illustrate complex interactions between different immune cell types in the tumor microenvironment and indicate these interactions play meaningful roles in patient survival. These results demonstrate the importance of personalized immune response profiles when studying the factors underlying tumor immunogenicity and immunotherapy response.

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers - The ASCO Post

2017-01-26T20:32:00.001-05:00

Number of New Cases and Deaths per 100,000: The number of new cases of ovarian cancer was 11.9 per 100,000 women per year. The number of deaths was 7.5 per 100,000 women per year. These rates are age-adjusted and based on 2009-2013 cases and deaths.
Lifetime Risk of Developing Cancer: Approximately 1.3 percent of women will be diagnosed with ovarian cancer at some point during their lifetime, based on 2011-2013 data.
~~~~~~~~~~~~~~~~~~
The ASCO Post

Posted: 1/26/2017

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20% of cancers diagnosed worldwide.

The trial is called DART (Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors) and is managed by SWOG, the cancer clinical trials group that is part of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN). The trial is sponsored by the NCI and being conducted under the NCI collaborative agreements with Bristol-Myers Squibb for ipilimumab (Yervoy) and nivolumab (Opdivo).

DART and NCI-MATCH
The trial draws on the design and takes advantage of the scale of another landmark trial offered through the NCTN, NCI-MATCH (NCI-Molecular Analysis for Therapy Choice), a precision medicine trial open at more than 1,000 clinical sites. Codesigned by the ECOG-ACRIN Cancer Research Group and the NCI, and led by ECOG-ACRIN, NCI-MATCH is the most sweeping precision medicine trial in the United States. NCI-MATCH uses a customized tumor gene testing method to match patients with any solid tumor, along with lymphoma and myeloma, to multiple targeted treatments. Currently, there are 24 treatments offered, with plans to add about 10 more. Since NCI-MATCH was launched in August 2015, more than 2,500 patients have completed tumor gene testing out of the 6,000 patients intended to be screened. As of December 1, 2016, nearly 300 patients have entered treatment arms.
According to the definition used for the DART trial, rare cancers are those diseases with less than a 6 in 100,000 incidences per year. These include dozens of types, including cancers in nerves, glands, bones, and skin. But only certain patients will be eligible to enroll in DART. To join, patients must be registered to NCI-MATCH. If they don’t have a treatment option under NCI-MATCH, or if they didn’t respond to treatment on that trial, and their rare cancer is eligible, they can enroll......

cute and happy pics in tweetoff: #cuteanimaltweetoff

2017-01-26T16:13:00.003-05:00

OVARIAN CANCER and US

open access Feb 13, 2018: The Yet Unrealized Promise of Ovarian Cancer Screening

The Yet Unrealized Promise of Ovarian Cancer Screening

References

You May Also Like

You May Also Like

Cancer Network(2) Lynch Syndrome Associated Ovarian Cancer/Endometrioid/Serous Carcinoma

Feb 6th Webinar: Looking Ahead: Ovarian Cancer Advocacy in 2017

Newly released 2017 Canadian Nonprofit Sector Salary & Benefits Report reveals current compensation trends

Cash compensation continues to grow slowly for many

OA: Mesh, graft, or standard repair for women having primary transvaginal anterior or posterior compartment prolapse surgery...

Interpretation

Familial Cancer journal January Index (not an OA publication)

(Seromucinous) Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary

Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers - The ASCO Post

cute and happy pics in tweetoff: #cuteanimaltweetoff

#cuteanimaltweetoff